Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cigna Corp (NY: CI )

319.77 +0.28 (+0.09%)
Official Closing Price Updated: 7:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cigna Corp

< Previous 1 2 3 4 5 6 7 8 9
...
25 26 Next >
3 Healthcare Stocks For Long-Term Growth And Dividends
Healthcare stocks will profit from the U.S. aging population and pay rising dividends over time. 
Via Talk Markets
Boomer Benefits Unveils Revamped 6-Day Mini-Course on Medicare
Fort Worth, Texas--(Newsfile Corp. - November 5, 2024) - Boomer Benefits, a leading Medicare insurance agency based in Fort Worth,... 
Via Newsfile
Price Over Earnings Overview: Cigna
Via Benzinga
MarketBeat Week in Review – 10/28 - 11/1
Stocks staged a strong rally on Friday following a steep sell-off; a weak jobs report all but guarantees a rate cut which adds to bullish sentiment 
Via MarketBeat
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Interest Rates
Cigna Group (CI) Q3 2024 Earnings Call Transcript
CI earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
NYSE:CI is an undervalued gem with solid fundamentals.
THE CIGNA GROUP (NYSE:CI): good value for what you're paying. 
Via Chartmill
Investors seeking growth at a reasonable cost should explore NYSE:CI.
THE CIGNA GROUP (NYSE:CI) is showing good growth, while it is not too expensive. 
Via Chartmill
11 Analysts Assess Cigna: What You Need To Know
Via Benzinga
Stocks Tumble, Nasdaq 100 Selloffs As Tech Giants Disappoint, Crypto Companies Plummet: What's Driving Markets Thursday?
Risk aversion swept across markets on Thursday as investor disappointment over third-quarter tech earnings triggered the steepest drop in major U.S. indices in nearly two months. 
Via Benzinga
Cigna's Q3 Profit Beats Street On Strong Demand For Pharmacy Benefit Management's Specialty Drugs, New Clients
Cigna reports Q3 sales of $63.7 billion, a 30% YoY increase, driven by Evernorth growth. Adjusted EPS of $7.51 beats estimates. 2024 EPS guidance reaffirmed. 
Via Benzinga
The Cigna Group Reports $63.7 Billion In Q3 Total Revenues, Better Than Expected
The Cigna Group has reported impressive financial results for the third quarter of 2024. 
Via Talk Markets
Here's How Much You Would Have Made Owning Cigna Stock In The Last 15 Years
Via Benzinga
$100 Invested In This Stock 15 Years Ago Would Be Worth $1,200 Today
Via Benzinga
A Glimpse Into The Expert Outlook On Cigna Through 11 Analysts
Via Benzinga
Cigna Considers Humana Acquisition – What It Means for the Stocks
Rumors swirl around a potential Cigna (CI) and Humana (HUM) merger, but Medicare Advantage costs pose a significant challenge, making the merger risky. 
Via MarketBeat
Jim Cramer: Buy Broadcom, But Stay Away From These Stocks
The "Mad Money" host recommends buying Broadcom, but staying away from this bus manufacturer. "I just don't see the growth." 
Via Benzinga
Why Cigna Group Stock Got Mashed on Monday
A media report stated that the company is determined to grow with a major merger deal. 
Via The Motley Fool
Stocks Fall As Treasury Yields, Dollar Rise; Nvidia Hits Record Highs: What's Driving Markets Monday?
U.S. major indices fell on Monday as rising Treasury yields and a strengthening dollar dampened risk sentiment. Investors are reassessing the economic outlook and weighing potential risks tied to the... 
Via Benzinga
Cigna And Humana Revive Early Merger Talks After Year-Long Pause As Medicare Cost Pressure Looms
Cigna and Humana are in early-stage merger discussions after a year-long pause. Amid financial pressure, Humana's Medicare Advantage star ratings have plummeted, impacting future revenue. 
Via Benzinga
Cigna-Humana Merger Talks Back On With Tables Turned; 2024 Election Is Key
Cigna-Humana merger talks are back on, nearly one year after the first try. The price may be more affordable after CI stock outperformed, while HUM struggled. 
Via Investor's Business Daily
Market Briefing For Monday, Oct 21
Investors need to recognize that this time of year not only are more 'shakeouts' than we've seen likely; but tax-selling and shuffling (rearranging the Titanic deckchairs to some degree) is to be... 
Via Talk Markets
SAP, Nucor And 3 Stocks To Watch Heading Into Monday
Via Benzinga
Pharmacy Retailer CVS Health Backs Away From Annual Forecast, Names New CEO
CVS Health replaces CEO Karen Lynch with David Joyner as the company struggles with lower earnings projections and rising medical costs. Q3 2024 results, including a $1.1 billion charge, are expected... 
Via Benzinga
CVS, UnitedHealth Request FTC Chair Recusal Amid Ongoing Pharmacy Benefit Managers Lawsuit
The FTC has filed a formal complaint accusing CVS, Cigna, and UnitedHealth of engaging in anti-competitive practices that inflate insulin prices. The complaint claims the PBMs' focus on rebates raises... 
Via Benzinga
3 Dividend Growth Stocks Set to Supercharge Your Portfolio
Cigna Group, CDW, and Coterra Energy are three stocks that offer a strong history of dividend payouts and the potential for continued dividend growth. 
Via MarketBeat
Topics ETFs
Shamus McGuire Champions Advanced Technology Integration in New Jersey’s Healthcare Sector
Via Get News
Topics Artificial Intelligence
Exposures Artificial Intelligence
Texas Attorney General Sues Insulin Manufacturers and Pharmacy Benefit Managers Over Price-Fixing Conspiracy That Increased Prices by 1,000%
Texas Attorney General Ken Paxton sues major insulin manufacturers and PBMs, accusing them of conspiring to inflate insulin prices by as much as 1,000%, violating Texas law and harming diabetes... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Healthcare Executive Shamus McGuire Highlights Work-Life Balance in New Jersey
New Jersey, US, 2nd October 2024, ZEX PR WIRE, Shamus McGuire, […] 
Via Zexprwire
CVS Health Mulls Split Of Retail And Insurance Divisions To Address Financial Challenges: Report
CVS Health explores splitting its retail and insurance units to address investor concerns and financial challenges. The potential breakup could unwind the $70 billion Aetna acquisition made in 2017. 
Via Benzinga
CVS Health in Focus as Activist Investor Prepares for High-Level Talks
CVS Health is under pressure from hedge fund Glenview Capital as the company grapples with stock price drops, financial struggles with Medicare, and legal scrutiny of its pharmacy-benefit unit. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
25 26 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.